1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18758
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorKlouvas, G.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorGiannakakis, T.en
dc.contributor.authorTsavaris, N.en
dc.contributor.authorKosmidis, P.en
dc.date.accessioned2015-11-24T18:54:51Z-
dc.date.available2015-11-24T18:54:51Z-
dc.identifier.issn0277-3732-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18758-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectBleomycin/administration & dosage/adverse effectsen
dc.subjectCarboplatin/administration & dosage/adverse effectsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInterferon-alpha/administration & dosage/adverse effectsen
dc.subjectMaleen
dc.subjectMelanoma/*drug therapy/pathology/secondaryen
dc.subjectMiddle Ageden
dc.subjectProspective Studiesen
dc.subjectRecombinant Proteinsen
dc.subjectVinblastine/administration & dosage/adverse effectsen
dc.titleRecombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanomaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8638545-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1996-
heal.abstractThirty-four patients with advanced malignant melanoma were treated with recombinant alpha-interferon (IFN) and chemotherapy consisting of carboplatin, vinblastine, and bleomycin (CVB). CVB was given for four cycles and IFN for 1 year or until progression. Of the 34 analyzed patients, 17 (50%) achieved an objective response, including two complete (6%) and 15 partial responses (44%). Responses were noted in cutaneous, lymph node, and pulmonary sites, with a median time to disease progression of 5 months (range, 3-20 months). The median survival from onset of therapy was 8 months (range, 1-22 months) for the 34 patients. Ninety-four percent of the patients experienced flu-like symptoms and 82% fatigue or weakness. Leukopenia grade 3-4 was observed in four patients (12%). There were two toxicity-related deaths (6%); one from bleomycin-induced pneumonitis and one from neutropenic sepsis. It is concluded that the addition of IFN to CVB regimen, in this study, showed no apparent advantage on response rates, disease-free interval, or survival. The observed treatment-related mortality was unacceptably high. IFN administered as maintenance therapy following CVB conferred no survival benefit.en
heal.journalNameAm J Clin Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons